Source: Eur Respir J, 57 (1) 2000348; 10.1183/13993003.00348-2020
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Susumu Sakamoto, Kensuke Kataoka, Yasuhiro Kondoh, Motoyasu Kato, Masaki Okamoto, Hiroshi Mukae, Masashi Bando, Takafumi Suda, Kazuhiro Yatera, Yoshinori Tanino, Tomoo Kishaba, Noboru Hattori, Yoshio Taguchi, Takefumi Saito, Yasuhiko Nishioka, Kazuyoshi Kuwano, Kazuma Kishi, Naohiko Inase, Shinichi Sasaki, Hajime Takizawa, Takeshi Johkoh, Fumikazu Sakai, Sakae Homma. Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial. Eur Respir J, 57 (1) 2000348; 10.1183/13993003.00348-2020

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized controlled phase 3 trial Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Inhaled beclomethasone/formoterol in idiopathic pulmonary fibrosis: a randomised controlled exploratory study Source: ERJ Open Res, 3 (4) 00100-2017; 10.1183/23120541.00100-2017 Year: 2017 Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial Source: International Congress 2018 – Clinical news in idiopathic interstitial pneumonias Year: 2018 Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial Source: Eur Respir J 2013; 42: 1622-1632 Year: 2013 Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study Source: Eur Respir Rev 2008; 17: 116-122 Year: 2008 Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis Source: Eur Respir J, 52 (2) 1800230; 10.1183/13993003.00230-2018 Year: 2018 Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Concomitant corticosteroid with anti-fibrotic therapy for idiopathic pulmonary fibrosis: a prospective multicenter study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 A comparison of pirfenidone versus nintedanib for the management of idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Azithromycin for the treatment of cough in idiopathic pulmonary fibrosis: A randomized controlled cross-over pilot trial. Source: Virtual Congress 2020 – Chronic cough: only symptom or disease? Year: 2020 Long-term efficacy and safety of N-acetylcysteine inhalation in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009 Real-life comparison between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Effects of combined therapy with nebulized b2-agonist and anticholinergic in severe exacerbation of chronic obstructive pulmonary disease. Randomized controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 611s Year: 2007 LATE-BREAKING ABSTRACT: Safety and tolerability of N-acetylcysteine (NAC) with pirfenidone in idiopathic pulmonary fibrosis (IPF): PANORAMA Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021 Idiopathic pulmonary fibrosis treatment: Combined pirfenidone + acetylcysteine vs N-acetylcysteine in monotherapy Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis Year: 2014 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Effect of high-flow oxygen therapy on exercise tolerance in idiopathic pulmonary fibrosis: a randomized crossover trial. Source: Virtual Congress 2021 – Best abstracts in pulmonary rehabilitation and chronic care Year: 2021 A Phase 2, double-blind, placebo-controlled study of N–acetylcysteine in combination with pirfenidone in patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 6 Year: 2014 Effect of bosentan on MMP-7 levels as add-on therapy in idiopathic pulmonary fibrosis. A prospective study Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011